MD

MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

MD posts a Q2 earnings beat as stronger cash collections and a favorable payor mix lift results despite lower volumes.

Pediatrix Medical Group NYSE: MD reported second-quarter 2026 adjusted EBITDA of $76 million and reaffirmed its full-year adjusted EBITDA outlook of $280 million to $300 million, as stronger revenue-cycle-management collections, payer mix and patient acuity offset lower patient-service volumes.

Pediatrix Medical Group, Inc. (MD) Q2 2026 Earnings Call Transcript

Pediatrix Medical Group (MD) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.53 per share a year ago.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Reports Second Quarter Results.

Pediatrix Medical Group (MD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group, Inc. (NYSE: MD) (“Pediatrix” or “the Company”), a leading provider of physician services, today provided an update on its second quarter 2026 business trends. In response to recent reports from other healthcare market participants regarding shifting utilization and reimbursement trends, the Company confirms that its payor mix for the second quarter remained stable and unchanged relative to recent historical trends and the Company'.